VEGFA and breast neoplasm: Inhibiting VEGF-A expression with bevacizumab, (a fully human anti-VEGF antibody) in SCID mice with established orthotopic MDA-MB-231 breast tumours caused reduced TAM infiltration which was correlated with reduced microvessel density and reduced VEGF-induced angiogenesis [20].